Processa Pharmaceuticals, Inc.

PCSA · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$3,437-$3,934-$2,834-$2,729
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$75$431$228$155
Change in WC-$375$1,437-$146$303
Other Non-Cash$252-$204$23$22
Operating Cash Flow-$3,484-$2,270-$2,730-$2,248
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$0-$1-$2-$1
Stock Issued$2,860$6,320$4,439$549
Stock Repurch.$1$0-$1-$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$9$0$0
Financing Cash Flow$2,856$6,310$4,436$548
Forex Effect$0$0$0$0
Net Chg. in Cash-$628$4,040$1,706-$1,700
Supplemental Information
Beg. Cash$6,937$2,897$1,191$2,891
End Cash$6,308$6,937$2,897$1,191
Free Cash Flow-$3,484-$2,270-$2,730-$2,248
Processa Pharmaceuticals, Inc. (PCSA) Financial Statements & Key Stats | AlphaPilot